Clínica universidad de Navarra

Madrid 28027

1 studies enrolling now · 12 studies all time

What they study most

Advanced Cancer, Advanced Endometrial Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Carcinoma, Hepatocellular, Cervical Cancer, Colorectal Cancer (CRC), Colorectal Neoplasms, Endometrial Neoplasms, Facial Angiofibroma, Follicular Lymphoma, Liver Neoplasms

Studies at this site

• FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC — Recruiting now
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. — Running, not enrolling
• A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) — Running, not enrolling
• Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors — Running, not enrolling
• A Study of ZW191 in Participants With Solid Tumors — Running, not enrolling
• A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) — Completed
• A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor — Running, not enrolling
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — Running, not enrolling
• A Study of AGEN2034 in Advanced Tumors and Cervical Cancer — Completed
• A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody — Running, not enrolling
• GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer — Withdrawn before enrolling
• Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex — Completed